Annual report pursuant to Section 13 and 15(d)

Segments - Narrative (Details)

v3.6.0.2
Segments - Narrative (Details)
3 Months Ended 12 Months Ended
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2016
USD ($)
Segment
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Segment Reporting Information [Line Items]                      
Number of reportable segments | Segment                 2    
Revenues $ 275,489,000 $ 298,035,000 $ 357,100,000 $ 291,037,000 $ 276,191,000 $ 143,034,000 $ 42,429,000 $ 30,084,000 $ 1,221,661,000 $ 491,738,000 $ 91,125,000
Intersegment Elimination                      
Segment Reporting Information [Line Items]                      
Revenues                 0    
Inter-segment allocation of interest expense                 $ 0    
Pfizer | Customer Concentration Risk | Sales Revenue, Net                      
Segment Reporting Information [Line Items]                      
Percentage of revenue contributed by customer                   13.00%  
Customer 1 | Customer Concentration Risk | Sales Revenue, Net                      
Segment Reporting Information [Line Items]                      
Percentage of revenue contributed by customer                     13.00%
Customer 1 | Customer Concentration Risk | Accounts Receivable                      
Segment Reporting Information [Line Items]                      
Percentage of revenue contributed by customer                 10.00% 10.00%